What's in UCB Japan Co. Ltd.'s pipeline?

UCB Japan Co. Ltd. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with UCB Japan Co. Ltd.'s portfolio?

Top competitors by shared drug class: Oslo University Hospital, Seoul National University Hospital, UCB Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ucb-japan-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

UCB Japan Co. Ltd. — Portfolio Competitive Intelligence Brief

UCB Japan Co. Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Levetiracetam (LEV)	Levetiracetam (LEV)	marketed	Antiepileptic drug (AED)	SV2A (synaptic vesicle protein 2A)	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Oslo University Hospital · 1 shared drug class
Seoul National University Hospital · 1 shared drug class
UCB Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UCB Japan Co. Ltd.:

Cite this brief

Drug Landscape (2026). UCB Japan Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ucb-japan-co-ltd. Accessed 2026-05-16.